Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.48%52 PS Ratio is 13.12 as of Aug. 10, 2026, which is 1% below its 10-year median of 13.22. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, TCM Biotech International ranks worse than 57.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TCM Biotech International's share price is NT$157.00.
TCM Biotech International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$11.97. Hence, TCM Biotech International's PS Ratio for today is 13.12.
The historical rank and industry rank for TCM Biotech International's PS Ratio or its related term are showing as below:
TPE:4169'
s PS Ratio Range Over the Past 10 Years
Min: 5.1 Med: 13.22 Max: 22.56
Current: 13.12
During the past 13 years, TCM Biotech International's highest PS Ratio was 22.56. The lowest was 5.10. And the median was 13.22.
TPE:4169's PS Ratio is ranked worse than 57.2% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs TPE:4169: 13.12
TCM Biotech International Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of TCM Biotech International was 45.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.10% per year.
During the past 13 years, TCM Biotech International's highest 3-Year average Revenue per Share Growth Rate was 19.70% per year. The lowest was -10.80% per year. And the median was 7.80% per year.
TCM Biotech International (TPE:4169) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
TCM Biotech International PS Ratio Related Terms
TCM Biotech International PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TCM Biotech International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's PS Ratio distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TCM Biotech International's Share Price of today is NT$157.00. TCM Biotech International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$11.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TCM Biotech International (TPE:4169) has a PS Ratio of 13.12 as of Aug. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TCM Biotech International and its competitors. This is near median its historical median of 13.22. Over the past decade, TCM Biotech International's PS Ratio has ranged from 5.10 to 22.56. According to the industry distribution chart, TCM Biotech International ranks #532 out of 930 companies in the Biotechnology industry, placing it in the top 57.2%.
Is TCM Biotech International's PS Ratio too high?
TCM Biotech International's current PS Ratio of 13.12 is near median its 10-year median of 13.22. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 22.56. The Biotechnology industry median PS Ratio is 9.51. TCM Biotech International's value of 13.12 is 38% above this industry median. Based on the distribution chart, TCM Biotech International ranks #532 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #532 out of 930 companies for PS Ratio. This places TCM Biotech International in the lower half of its industry. The industry median PS Ratio is 9.51. TCM Biotech International's value of 13.12 is 38% above this benchmark. Historically, TCM Biotech International's own PS Ratio has ranged from 5.10 to 22.56 over the past decade. While the company's 10-year median is 13.22 vs. the industry median of 9.51, TCM Biotech International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.51, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current PS Ratio of 13.12 is 38% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median PS Ratio is 9.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current PS Ratio is 13.12, which is near median its own 10-year median of 13.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current PS Ratio is 13.12, which is near median its 10-year median of 13.22 and 38% above the Biotechnology industry median of 9.51. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current PS Ratio is 13.12 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
PS Ratio: 13.12 (near median its 10-year median of 13.22)
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
Industry Position: 38% above the Biotechnology median (#532 of 930)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
